Loss of UFMylation supports prostate cancer metastasis and rewires cell metabolism towards hexosamine biosynthesis
Authors:
- Laura Bozal-BasterraLBLaura Bozal-Basterra
- Ana Margarida Ferreira CamposACAna Margarida Ferreira Campos
- Margherita DemiccoMDMargherita Demicco
- Klaudia SobczakKSKlaudia Sobczak
- June Ereño-OrbeaJune Ereño-Orbea
- Patricia Altea-ManzanoPAPatricia Altea-Manzano
- Belén Martínez La OsaBOBelén Martínez La Osa
- Saioa Garcia-LongarteSaioa Garcia-Longarte
- María Ponce-RodriguezMPMaría Ponce-Rodriguez
Preprint
Abstract
The acquisition of metastatic features in tumor cells encompasses genetic and non-genetic adaptation, including reprogramming of cellular metabolism. Here we show that loss of UFMylation reroutes glucose metabolism, promotes invasive capacity and supports prostate cancer metastasis. Through transcriptome-based bioinformatics analysis, we identified a reduction in the ubiquitin-like modifier UFM1 and its ligase UFL1 in metastatic prostate cancer. We demonstrate that loss of UFMylation results in enhanced cancer cell dissemination and a switch from cellular proliferation to invasion. Using biotin-based proteomics, we identified phosphofructokinase (PFKAP) as an unprecedented UFMylation substrate. Consistent with UFMylation playing a role in the regulation of phosphofructokinase activity, loss of UFMylation reduced glucose metabolism in favour of hexosamine biosynthesis, which resulted in elevated glycosylation of proteins relevant for cell invasion. These results reveal a role for UFMylation in the regulation of phosphofructokinase and glucose metabolism to support prostate cancer metastasis.Keywords
Funding Information
- EMBO (Scientific Exchange Grant (#10477))
- Basque Department of Industry, Tourism and Trade
- Fundación CRIS contra el cancer (PR_EX_2021-22)
- Fundación CRIS contra el cancer (PR_TPD_2020-19)
- Severo Ochoa Excellence Accreditation (CEX2021-001136-S)
- iDIFFER network of Excellence (RED2022-134792-T)
- AstraZeneca Foundation (award to young investigators 2023)
- Leonardo Grant for Scientific Research and Cultural Creation (Beca Leonardo LEO23-2-10984-BBM-TRA-261)
- CIBERONC (CIBERONC)
- Marie Sklodowska-Curie Actions Individual Fellowship (MSCA-IF-2018-839896)
- FWO projects (FWO Projects)
- Fonds Baillet Latour, KU Leuven (Fonds Baillet Latour, KU Leuven)
- MIT Center for Precision Cancer Medicine (MIT Center for Precision Cancer Medicine)
- NCI (R35CA242379)
- NCI (R01CA259253)
- NCI (P30CA1405141)
This publication has 49 references indexed in Scilit:
- Human UFSP1 is an active protease that regulates UFM1 maturation and UFMylationCell Reports, 2022
- A missense mutation in DDRGK1 gene associated to Shohat‐type spondyloepimetaphyseal dysplasia: Two case reports and a review of literatureAmerican Journal of Medical Genetics Part A, 2022
- Genomic profiling of the UFMylation family genes identifies UFSP2 as a potential tumour suppressor in colon cancerClinical and Translational Medicine, 2021
- 13C Tracer Analysis and Metabolomics in 3D Cultured Cancer Cells2018
- Glycosylation is an Androgen-Regulated Process Essential for Prostate Cancer Cell ViabilityEBioMedicine, 2016
- UFMylation: A Unique & Fashionable Modification for LifeGenomics, Proteomics & Bioinformatics, 2016
- A roadmap for interpreting 13 C metabolite labeling patterns from cellsCurrent Opinion in Biotechnology, 2015
- Correction of13C Mass Isotopomer Distributions for Natural Stable Isotope AbundanceJournal of Mass Spectrometry, 1996
- The Use of Glycosylation Inhibitors to Study Glycoconjugate Function1993
- Glycoprotein synthesis and inhibition of glycosylation by tunicamycin in preimplantation mouse embryos: Compaction and trophoblast adhesionCell, 1979